Michael Porter of Harvard Business School has Joined the Board of Directors of ExThera Medical Corporation

Michael Porter, Ph.D., has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company focused on the therapeutic reduction of drug-resistant pathogens and sepsis mediators in whole blood. ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) has a CE Mark in Europe for the treatment of a wide range of bloodstream infections. In the USA Seraph 100 has Emergency Use Authorization from FDA, where it is being used successfully in the treatment of COVID-19 patients, many of whom are critically ill.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005367/en/

Michael Porter (Photo: Business Wire)

Professor Porter, the Bishop William Lawrence University Professor at Harvard Business School, is recognized as a leading authority on competitive strategy, the competitiveness and economic development of nations and regions, and the application of competition and strategy principles to address social problems such as health

Read More